Post-tuberculosis lung health: perspectives from the First International Symposium

B. W. Allwood,1 M. M. van der Zalm,2 A. F. S. Amaral,3 A. Byrne,4 S. Datta,5,6,7 U. Egere,8 C. A. Evans,5,6,7 D. Evans,9 D. M Gray,10 G. Hoddinott,2 O. Ivanova,11 R. Jones,12 G. Makanda,13 F. M. Marx,2,14 J. Megheji,15 S. Mpagama,16 J. G. Pasipanodya,17 A. Rachow,11,18 I. Schoeman,13 J. Shaw,1 C. Stek,19,20 S. van Kampen,21 D. von Delft,13 N. F. Walker,15,22 R. S. Wallis,23 K. Mortimer24,25

1Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, 2Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa; 3National Heart and Lung Institute, Imperial College London, London, UK; 4Heart Lung Clinic, St Vincent’s Hospital Clinical School, University of New South Wales, Sydney, NSW, Australia; 5Department of Infectious Disease, Imperial College London, London, UK; 6Innovation For Health And Development, Laboratory for Research and Development, Universidad Peruana Cayetano Heredia, Lima, 7Innovacion por la Salud y el Desarrollo, Asociación Benéfica Prisma, Lima, Peru; 8IMPALA Consortium and Community Health Systems Group, Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK; 9Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 10Division of Paediatric Pulmonology, Department of Paediatrics, University of Cape Town, Cape Town, South Africa; 11Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany; 12Faculty of Health, Plymouth University, Plymouth, UK; 13TB Proof, Cape Town, South Africa; 14DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis, Faculty of Science, Stellenbosch University, Johannesburg, South Africa; 15Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK; 16Kibong’oto Infectious Diseases Hospital, Kibong’oto, Tanzania; 17Center for Infectious Diseases Research & Experimental Therapeutics, Texas Tech University Health Sciences Center, Dallas, TX, USA; 18German Centre for Infection Research (DF Iz), Partner Site Munich, Munich, Germany; 19Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; 20Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; 21Leiden University Medical Center, Leiden, The Netherlands; 22Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK; 23Aurum Institute, Johannesburg, South Africa; 24Liverpool School of Tropical Medicine, Liverpool, UK; 25International Union against Tuberculosis and Lung Disease, Paris, France

ALTHOUGH CURABLE, TB frequently leaves the individual with chronic physical and psycho-social impairment, but these consequences have been largely neglected. The 1st International Post-Tuberculosis Symposium (Stellenbosch, South Africa) was held to discuss priorities and gaps in addressing this issue. A barrier to progress has been the varied terminology and nomenclature, so the Delphi process was used to achieve consensus on definitions. Lack of sufficient evidence hampered definitive recommendations in most domains, including prevention and treatment of post-TB lung disease (PTLD), but the discussions clarified the research needed.

A consensus was reached on a toolkit for future PTLD measurement and on PTLD patterns to be considered. The importance of extra-pulmonary consequences and progressive impairment throughout the life-course was identified, including TB recurrence and increased mortality. Patient advocates emphasised the need to address the psychological and social impacts post TB and called for clinical guidance. More generally, there is an urgent need for increased awareness and research into post-TB complications.

KEY WORDS: post-tuberculosis; impairment; sequelae; lung health; lung disease

TUBERCULOSIS (TB) IS THE LEADING cause of death worldwide from an infectious disease, with an estimated 10 million cases and 1.5 million deaths in 2018.1 On the positive side, the World Health Organization estimates that more than 58 million people have survived TB in this century alone.1 However, unlike many other respiratory infections, TB has the propensity to leave host tissues permanently damaged or destroyed. It thereby transitions from being a treatable communicable disease, into a chronic morbidity in both adults and children. The fate of TB

Correspondence to: Brian Allwood, Department of Medicine, 3rd Floor, Clinical Building, Francie Van Zijl Drive, Medical School, Tygerberg 7505, South Africa e-mail: brianallwood@sun.ac.za

Article submitted 6 February 2020. Final version accepted 6 May 2020.
survivors is uncertain, and the long-term outcomes and drivers of morbidity and mortality after TB cure have historically been neglected areas of research. Post-TB morbidities include both physical impairments, such as chronic lung and other organ impairments, and psychosocial morbidities, including ongoing stigma, anxiety/depression, social isolation and persistent socioeconomic impairment. The true burden of each of these remains poorly described, although a growing literature describes shortened survival post-TB. Mortality rates for TB survivors may be as high as three times controls, while prevalence estimates for lung impairment after pulmonary TB vary from 18–87% depending on the population studied. The true burden of each of these remains poorly described, although a growing literature describes shortened survival post-TB. Mortality rates for TB survivors may be as high as three times controls, while prevalence estimates for lung impairment after pulmonary TB vary from 18–87% depending on the population studied.

Even if these disease burden estimates are inflated, given the 10 million annual new cases of TB each year, post-TB morbidity is likely to be one of the most important causes of chronic lung disease globally. However, its impact is presently hidden in the low and middle-income countries where clinical services, research and advocacy remain inadequate. Additionally, people completing TB treatment remain at increased risk of developing TB again. Importantly, TB affects not just the individual, but also their households and communities, and these broader impacts have not been fully evaluated. Catastrophic costs can be incurred by 32–83% of TB-affected households related to TB care, and it is unknown if families ever fully recover.

The problems encountered after TB are not new, but have yet to be addressed by national TB programs or funding agencies. Only a small fraction of the estimated US$6.8 billion expended by countries on TB control, or the estimated US$ 772 million spent on TB research has been directed to life and wellness after ‘cure’. Here we present a summary of the outcomes of the various workshops held at the symposium (http://www.post-tuberculosis.com).

**STRUCTURE AND AIMS**

Conceptualised and implemented by an international steering committee, the symposium had the five aims presented in Table 1. The symposium was structured as a working meeting with presentations and workshops covering a range of overlapping aspects of life and illness after TB (Figure). The workshops provided a forum for discussion of existing data and knowledge gaps. The steering committee made use of the Delphi Technique to reach consensus. In brief, the Delphi Technique is a structured systematic communication method which relies on a panel of experts. It uses a list of questions that is developed and refined in

| Table 1 | Aims of the 1st Post-Tuberculosis Symposium |
|---------|---------------------------------------------|
| Aim 1   | To advocate for patients suffering with post-TB complications |
| Aim 2   | To facilitate face-to-face networking between leaders in the field |
| Aim 3   | To define the current state of knowledge surrounding post-TB diseases |
| Aim 4   | To discuss and achieve consensus on important aspects of post-TB lung diseases |
| Aim 5   | To produce a reference document for researchers and workers in the field |

TB = tuberculosis.
several rounds. The process is iterative, where anonymously obtained information is recorded and reported to delegates regularly. By ‘confronting’ the delegates with each other’s ideas and insights in each new round, consensus opinion is built. The process was repeated until the threshold for agreement, set at 66%, was reached.

Consensus on terminology

A major barrier to progress in this emerging field has been a lack of consensus in terminology and nomenclature. Priority was given to achieving consensus in terminology, to effectively categorise and easily identify relevant literature. Existing terminology used to describe the long-term effects of TB following treatment completion, were identified from the literature. Using three rounds of the Delphi process, all delegates voted with a majority vote of 84% to embrace the term ‘post-tuberculosis’. This term is proposed as a prefix or adjective to describe residual morbidity after TB and may be used within publications or as a key word for manuscript search terms.

Additionally, delegates within workshops reached consensus on the specific terms of ‘lung disease/s’ to describe the lung complications after TB (‘post-tuberculosis lung disease/s (PTLD)’), and ‘economic, social and psychological (ESP) well-being’ to describe the psycho-social complications after TB (‘post-tuberculosis economic, social and psychological well-being’ (Post-TB ESP)’). This nomenclature will be re-assessed and reviewed as new data emerge.

Epidemiology of post-tuberculosis lung disease

The aims of the workshop were to discuss 1) current knowledge on disease burden due to PTLD, 2) relevant PTLD-outcomes including how they are measured and reported in epidemiological and clinical studies and 3) current evidence on risk factors for PTLD.

The workshop participants agreed that whilst there is strong evidence for the existence of PTLD, estimating its precise burden remains challenging. Reasons for this include 1) diversity in clinical phenotypes, 2) heterogeneity of outcome measures, and 3) variable methodology for estimating the fraction of post-TB lung abnormalities directly attributable to TB and a lack of adequate control for confounders. The risk factors for the development of PTLD are also poorly established.

Apart from concrete PTLD case definitions, a common methodological framework describing the relevant diagnostic tools and interpretation strategies for the measurement of PTLD and associated risk factors was called for, with specific guidelines on the interpretation and grading of results from each PTLD assessment tool (see below). Where adapted guidelines for PTLD are missing, existing guidelines and standardised testing instructions, including questionnaires, showing the best fit to the studied population should be chosen. Reports on PTLD-outcomes should include a detailed description of the methodology used and provide explanation on reasons for selection.

Additionally, potential research gaps related to PTLD were identified and how to address these in future clinical or epidemiological studies was discussed. There was agreement that next to proper case definitions, the different phenotypes of PTLD should be better characterised. Further follow up studies are needed to define the clinical outcomes that are meaningful for PTLD-related morbidity and mortality. Finally, the role of the long list of potential risk factors, such as environmental, occupational, clinical and behavioural exposures, affecting the development of PTLD deserve further investigation.

Minimum case definition of post-tuberculosis lung disease

Participants highlighted the need for a PTLD case definition to be: broad and inclusive with sensitivity prioritised over specificity; be suitable for use in low and high resource settings; allow for dual-pathology with both PTLD and other respiratory pathologies occurring together; allow for patients to have both PTLD from an old episode of TB disease and a recurrent episode of active TB disease. It was acknowledged that lung damage can be asymptomatic, but may still be relevant to patient outcomes, and that individuals who may have had a previously undocumented or untreated episode of pulmonary TB may still have PTLD. Finally, it was noted that dual pathologies are widely seen, and it can be challenging to identify the primary contributor of a patient’s symptoms.

After three Delphi rounds, participants agreed on the following minimum case definition:

Evidence of chronic respiratory abnormality, with or without symptoms, attributable at least in part to previous tuberculosis.

Measurement toolbox

There are multiple approaches to measuring PTLD, and there was recognition that standardisation of approaches and tools is preferable but is limited by variable access to resources between settings, and lack of prospective data to inform which ‘core’ aspects of disease or measurements best predict long-term outcomes.

Delegates generated a list of potential approaches (or a ‘toolbox’), from which professionals can choose an approach to measure PTLD according to their available resources (Table 2). Although it is not possible to standardise measurement tools at present, the need for standardisation and quality control was highlighted. The importance of measuring co-exposures or co-morbidities was discussed and a potential list included.
There was unanimous agreement that a validated severity scoring system for PTLD would be of great value to identify patients at highest risk of adverse outcome, for both clinical and research purposes. Agreement was reached that a single, simple, easy to use scoring tool should be developed for use in both high- and low-resource settings, with flexibility according to available tests. Potential outcome measures against which this score could be derived included: mortality; health related quality of life; rate of lung function decline; rates of exacerbations/hospitalisations; as well as rates of TB recurrence. There was no consensus around a single outcome to be prioritised, and although mortality is likely the most important, all were felt to be meaningful. The challenge of deriving severity scores using a composite outcome, was highlighted and more prospective data are required to derive such scores.

Severity scores

Clinical patterns

The patterns of lung damage caused by TB are diverse and vary both between and within individuals. A ‘core’ list of patterns of PTLD seen in clinical practice was developed (Table 3). These patterns may occur with or without symptoms, and that an individual patient may have multiple patterns. Definitions were not discussed in the workshop, but suggestions have been provided for future review. It is anticipated that the PTLD management strategies developed can be targeted towards these core clinical patterns of disease, and these will evolve over time.

Pathogenesis and prevention of damage

This workshop examined mechanisms and basic science of TB disease, focusing on the interaction between host, pathogen and environment in the pathophysiology of tissue damage and the potential for host-directed therapies (HDT) to prevent damage. Key objectives were: 1) to identify pathophysiological...
**Table 3** Suggested PTLD clinical patterns with preliminary definitions (all categories are assumed to meet basic PTLD minimum case definition)

| Compartment       | Clinical patterns                     | Suggested definition*          |
|-------------------|---------------------------------------|--------------------------------|
| Airways           | TB-associated obstructive lung disease| Airway obstruction (FEV₁/FVC ratio < 0.7 OR < LLN) thought to be primarily related to small airway disease |
|                   | Bronchiectasis                         | CT definition (evidence of airway dilatation) > diameter of adjacent vessel, or non-tapering, OR CXR definition (evidence of ring and tramelines) |
| Parenchyma        | Cavitation                             | A gas-filled space either within an area of pulmonary consolidation, or surrounded by a thin wall |
|                   | Parenchymal destruction                 | Extensive destruction of lung tissue, with a gas-filled space occupying the volume of ≥1 lobe |
|                   | Fibrotic change                        | Areas of parenchymal scarring, with associated volume loss |
|                   | Aspergillus-related lung disease        | Evidence of aspergilloma on imaging OR chronic pulmonary aspergillosis on imaging and blood testing |
| Pleural           | Chronic pleural disease                | Evidence of pleural thickening on CXR or CT imaging |
| Pulmonary vascular| Pulmonary hypertension                 | Elevated pulmonary artery pressures as estimated using doppler echocardiography or measured at right heart catheterisation |
| Other             | Other                                  | Other pathology, not meeting the criteria above |

*These definitions were not discussed at the Symposium, but are included as suggestions, and are expected to evolve as new data emerge.

PTLD = post-TB lung disease; TB = tuberculosis; FEV₁ = forced expiratory volume in 1 s; FVC = forced vital capacity; LLN = lower limit of normal; CT = computed tomography; CXR = chest X-ray.

Pathways for investigation; 2) to review the current landscape of HDT trials; 3) develop consensus on appropriate endpoints for HDT trials; and 4) to prioritise knowledge gaps, highlighting areas for further research.

Talks highlighted evidence from cellular, ex-vivo, animal and human observational studies indicating a key role for host immune responses in pulmonary tissue damage during active TB, including: host-derived matrix metalloproteinase activity; neutrophil fate (apoptosis, necrosis or netosis); the balance of arachidonic acid derivatives in the release of pro- and anti-inflammatory cytokines; macrophage fate (neos- or necrosis) affecting *M. tuberculosis* survival and the extent of the subsequent host inflammatory response that ensues. There is a need to develop HDT which interrupt specific pathways, focusing on preventing and resolving cell death, matrix destruction and fibrosis, which are considered the primary drivers of morbidity. Two broad categories of HDT were described: those that primarily reduce inflammation or interrupt specific mechanisms for tissue damage, and those that primarily induce antimicrobial activity in phagocytic cells. A wide range of anti-inflammatory cytokines and anti-inflammatory cytokines have been tested to date, including corticosteroids, anti-TNF-alpha agents, phosphodiesterase inhibitors, anti-oxidants, and mTOR inhibitors. Ongoing or planned trials of antimicrobial HDT include vitamin D, auranofin (an oral gold salt), metformin (an AMPK activator), and imatinib (a tyrosine kinase inhibitor). The majority of these trials are designed to test drugs already licensed for other indications.

During the workshop, priority was given to the most suitable endpoint for HDT trials, as the majority of trials have focused on time to culture conversion as the sole primary endpoint of HDT trials. However, there was no agreement on whether microbiological endpoints should be part of a co-primary endpoint. Those in favour of including a microbiological endpoint argued that it is important in establishing that there is no harm by possible HDT; those opposed argued that this outcome in itself should not dictate whether a possible HDT is successful in improving lung damage (e.g. inflammation) or other long-term outcomes. Other endpoints discussed were similar to the toolkit presented above (Table 2) but additionally included PET/CT scanning; TB relapse and other biomarkers.

The following recommendations on clinical trial design and candidate agents for evaluation were agreed (Table 4): 1) There is a need to develop a pathway from basic science to HDT clinical trials. 2) More clarity is required on PTLD definitions, as discussed above, and outcomes to inform HDT clinical study design. 3) It is unlikely that there will be a ‘one size fits all’ preventative or HDT approach. 4) HDTs may adversely affect microbiological outcomes (i.e. promote discordant microbiological and lung health outcomes) and thus may have the potential to worsen lung damage. 5) All future HDT trials should include post-TB endpoints. 6) HDT trials should include people living with HIV infection.

**Lung complications in children**

Despite increasing awareness of PTLD in adults, there are no data available in children. It is well documented that early life lung function ‘tracks’ throughout life, pulmonary TB early in life could therefore have long-lasting and devastating consequences on lung health. A better understanding of the impact of PTB on long-term respiratory morbidity in children is urgently needed.

There are challenges to the diagnosis of PTLD in children, including that TB diagnosis is made on
clinical grounds in the majority of children.16 There was agreement that the ‘clinically diagnosed or unconfirmed’ TB cases should be included when investigating PTLD. In addition, the participants identified the need to advocate for PTLD as a clinical diagnosis in children with suspected TB and a history of TB, while carefully excluding active TB disease. The group proposed the following minimum case definition for PTLD in children:

Evidence of chronic respiratory impairment in an individual previously adequately treated for pulmonary tuberculosis in whom active tuberculosis is excluded, and in whom no other cause of chronic lung disease is the predominant cause.

The case definition may require adaptation as more evidence becomes available.

There is a lack of awareness and funding in this field and long-term follow-up cannot be recommended as standard of care in routine services where the healthcare system is already overburdened. Studies are currently underway determining the long-term burden of TB on lung health in children. This data is required to obtain first estimates of the burden and spectrum of PTLD in children, especially since we expect PTLD to be heterogenous between the different age groups.

Finally, the working group strongly recommended that TB and its consequences should be viewed as a life course disease and incidents that happen in early childhood should be included and probed when reviewing disease later in life.

Social, economic and psychological impact
There is little evidence available on social, economic and psychological consequences of TB after treatment completion.10 We do know that a substantial proportion of TB survivors have chronic respiratory disorders impairing quality of life (QoL), which are likely to place a continued financial burden on them, their families, their communities, and their health systems.17 The global impact of TB-disease is most likely underestimated because measures of disease burden (such as disability-adjusted life year) do not consider residual disability after treatment completion.

The main aim of this workshop was to map existing evidence, identify main research gaps and generate research questions on the social, economic and psychological impact of TB after cure.

Very little data and literature exists in this area, and there is an urgent need to both quantify and qualify TB patient experiences beyond TB cure. The highest priority gaps identified (Table 4) were 1) at the individual level: longitudinal data on clinical symptoms and lung impairment after TB together with

| Topic                                      | Priority areas and research priorities                                                                 |
|--------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Epidemiology of PTLD                      | Common methodological framework across studies                                                        |
|                                            | Follow-up studies defining meaningful clinical outcomes                                               |
|                                            | Investigation of factors affecting development of PTLD (e.g., environmental, occupation, clinical and behavioural factors) |
|                                            |                                                                                                       |
| Lung complications after TB               | Validation of tools used in PTLD                                                                       |
|                                            | Evaluation of clinically meaningful phenotypes and predictors of morbidity and mortality               |
|                                            | Development of validated severity scoring system                                                      |
| Pathogenesis and prevention               | Development of pathways from basic science to HDT trials                                               |
|                                            | Assessment of most meaningful endpoints in HDT trials                                                 |
|                                            | Clinical trials of HDTs                                                                               |
| Pulmonary consequences of TB in children  | Obtain disease estimates of burden of disease                                                          |
|                                            | Obtain estimates of spectrum of disease                                                                |
|                                            | Retrospective analysis of existing diagnostic, observational and treatment data                        |
| Social, economic and psychological impact  | For the individual: report disability (e.g., quality of health, mental health, pain, TB-related stigma), economic consequences and proportion facing catastrophic total costs |
|                                            | For the community: quantify the economic and social impact of social and family networks               |
|                                            | For the health system: determine the cost of residual disability to the health system                  |
| Treatment and holistic management         | Optimal timing of assessment for post-TB complications                                                 |
|                                            | Non-pharmacological studies: pulmonary rehabilitation, education on self-management, airway clearance techniques |
|                                            | Pharmacological studies: bronchodilators (e.g., long-acting beta-agonists, long-acting anti-muscarinic agents) |
| Health care systems                       | Prioritisation of advocacy for research funding to generate needed evidence                            |
|                                            | Development of guidelines for clinicians using available evidence and expert opinion                   |
|                                            | Engagement of international organisations, professional bodies and pharmaceutical industries            |
| Role of people affected by TB             | Peer group support and community interventions to reduce stigma                                       |
|                                            | Sustainable funding for affected community-driven advocacy and support for their involvement in research, policy and programmatic decisions |
|                                            | Former patient engagement to address recurrent TB                                                     |

TB = tuberculosis; PTLD = post-TB lung disease; HDT = host-directed therapy.
other indicators such as mental health, disability, QoL, TB-related stigma etc.; 2) at the individual, household and family level: data on the magnitude and main drivers of different types of costs (direct and indirect) incurred by TB patients and their households after TB cure; economic impact of TB (e.g. work productivity, proportion facing catastrophic total costs etc.)

There was consensus on the need for follow-up after TB treatment as evidence emerges for increased mortality, morbidity and recurrence risk in the post-TB period. At a minimum, lung function evaluation should be performed in order to detect and better specify possible lung function impairment. This assessment should help to identify patients suitable for pulmonary rehabilitation; best practices on how to provide health education and information about ‘after cure life’ during treatment. While tools are available (Table 1) or can be adapted address these research gaps, there is a need for robust epidemiological studies and large multi-country cohort studies.

Treatment and holistic management

Only 56 studies addressing treatment and management of PTLD have been published, with the majority assessing lung surgery and ventilation techniques, and almost no studies specific to PTLD. Only a few small studies assessing pulmonary rehabilitation and medication are available and were discussed. There was agreement that existing TB treatment guidelines are inadequate for the diagnosis, prevention and treatment of PTLD, for which no guidelines exist. Although specific guidelines are urgently needed, it is challenging due to lack of evidence for treatment specific to PTLD, and the diversity and spectrum of PTLD outcomes. Additionally, there is no evidence to either support or refute the use of the majority of existing respiratory treatments used in other chronic lung diseases (e.g. COPD, bronchiectasis etc.) being extrapolated to PTLD patients.

There was consensus on the need for follow-up after TB treatment as evidence emerges for increased mortality, morbidity and recurrence risk in the post-TB period. At a minimum, lung function evaluation should be performed in order to detect and better specify possible lung function impairment. This assessment should help to identify patients suitable for pulmonary rehabilitation. There is not yet universal agreement on the setting (in- or outpatient) and characteristics of pulmonary rehabilitation (e.g., psychological support, education, exercise, pharmaceutical treatment and oxygen) in patients with PTLD, however, local and economical resources need to be taken into consideration when developing guidelines.

A list of health outcomes to measure success of PTLD management strategies in clinical settings was proposed similar to the ‘Post-TB toolbox’ (Table 2) and included mortality. More research is urgently needed on the effectiveness and comparative cost of PTLD treatment options including: pulmonary rehabilitation; education about self-management; airway clearance and bronchodilators.

Health care systems

This workshop discussed health systems as the foundation for post-TB care and explored opportunities to impact health systems through advocacy to improve quality of care at every step in the TB care cascade. The workshop drew from presentations on health systems bottlenecks of care, personal testimonies and experiences of survivors, a human centered design approach where participants debated prioritisation of barriers in the TB care cascade.

Two priority areas for advocacy were identified: 1) evidence gaps in post-TB health and wellbeing; 2) lack of clinical guidelines and algorithms for the management of PTLD including the counselling of TB patients. The workshop therefore recommended 1) Prioritisation of advocacy for funding of research needed to generate evidence. Such research must address cost effectiveness of interventions and QoL; 2) Development of a guideline for clinicians, drawing on the current evidence base and expert opinion where necessary, and made available in collaboration with The Union. This will be reviewed as more evidence becomes available; 3) Development of integrated counselling services for TB patients in health systems.

The workshop recommended engagement of several groups including international organisations, professional bodies, pharmaceutical and other health-care technology industries, TB affected communities and former TB patients as advocacy partners.

The role of people affected by TB

The aim of this workshop was to reflect on the role of former TB patients, their families and communities in the context of the End TB Strategy and its first pillar: ‘Integrated, patient-centred tuberculosis care and prevention’. Two central topics were addressed. First, how to involve former patients in TB advocacy, mentoring and support of new patients and communities. Second, to reduce the burden of recurrent TB, we explored potential challenges to providing targeted health-care solutions to former patients.

Research has shown how former patients have assisted in finding missing people with TB, increasing the uptake of screening for latent infection and preventative therapy among household contacts, and improving treatment completion. There was also a discussion of the detrimental effect of stigma in communities, its impact on diagnostic delays and treatment non-completion. This emphasised the importance of clinic and workplace sensitivity to unique patient experiences as being central to prevent enacted stigma from health workers and discriminatory practices from employers, both infringements on human rights. The
importance of peer group support and interventions improving community knowledge to reduce internalised and anticipated stigma were emphasised.29

The group identified the need for sustainable funding of advocacy work by former patients, to ensure better access to new innovations, person-centred research, and the community involvement in policy and programmatic decisions.30 Former patients remain at high risk of TB even after completion of adequate treatment5 and therefore require solutions to prevent recurrence and reduce transmission within communities.6–31 The group recommended that former patients be engaged in the design of new integrated solutions of post-treatment health-care programs to address the prevention and management of both recurrent TB and PTLD. Finally, patient advocates called for the urgent development of clinical guidelines for the management of patients PTLD, which can be updated as evidence emerges.

CONCLUSION

Despite major global advances in the diagnosis and treatment of TB, it is unlikely to be eradicated within the next few decades, and the long-term complications are largely not addressed. This symposium was an important step towards highlighting the physical, psychological and socio-economic suffering that continues long after treatment completion. The difficulty in making definitive recommendations in many domains was determined by the astounding lack of data, emphasising the fact that this area has largely been overlooked by TB programs, funders, clinicians and researchers.

There is an urgent need for advocacy, increased awareness, and funding of research to provide the evidence base needed to develop robust guidelines. Advocacy should be multi-disciplinary and involve individuals affected by TB. Prevention of TB (and therefore post-TB complications) should remain a primary goal, but there may already be millions of adults and children with post-TB sequelae for whom prevention is too late. Urgent solutions are needed to relieve suffering and prolong life amongst former patients, and to mitigate the impact of post-TB disability on the households and communities in which they live. There is a need for guidelines to assist health care providers managing these individuals in the field, which will need to be frequently updated as better evidence unfolds (Table 4).

Only by working together – and in strong collaborative networks – will we be able to rapidly address this previously unspoken epidemic emerging from the shadows of TB.

Acknowledgements

The symposium was made possible through assistance from The International Union Against Tuberculosis and Lung Disease, Stellenbosch University, the Desmond Tutu TB Centre, and the National Institute for Health Research (NIHR) (IMPALA, grant reference 16/136/35) using aid from the UK Government to support global health research. The Steering Committee would like to gratefully acknowledge these contributions. MvdZ is part of the EDCTP2 programme supported by the European Union (grant number 99726 TB- Lung FACT TMA 2015 CDF - 1012).

No organisation was involved or had influence on the symposium content, this manuscript or the decision to publish. The views expressed are those of the author(s) and not necessarily those of their employers. All authors contributed to the preparation of this manuscript.

Conflicts of interest: none declared.

References

1 World Health Organization. Tuberculosis Fact Sheet. Geneva, Switzerland: WHO, 2020. https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed June 2020.
2 Datta S, Evans C A. Healthy survival after tuberculosis. Lancet Infect Dis 2019; 19: 1045–1047.
3 Romanowski K, Baumann B, Basham C A, et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2019; 3099: 1–9.
4 Ravimohan S, Kornfeld H, Weissman D, et al. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev 2018; 27: 170077.
5 Panjabi R, Comstock G W, Golub J E. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007; 11: 828–837.
6 Marx F M, Floyd S, Ayles H, et al. High burden of prevalent tuberculosis among previously treated people in 24 African communities suggests potential for targeted control interventions. Eur Respir J 2016; 48: 1227–1230.
7 Fuady A, Houweling T A J, Mansyur M, et al. Catastrophic total costs in tuberculosis-affected households and their determinants since Indonesia’s implementation of universal health coverage. Infect Dis Poverty 2018; 7: 3.
8 World Health Organization. Global tuberculosis report, 2019. Geneva, Switzerland: WHO, 2019.
9 McMillan S S, King M, Tully M P. How to use the nominal group and Delphi techniques. Int J Clin Pharm 2016; 38: 653–662.
10 van Kampen S C, Wanner A, Edwards M, et al. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. BMJ Glob Health 2018; 3: e000745.
11 Amaral A F S, Coton S, Kato B, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J 2015; 46: 1104–1112.
12 Stek C, Allwood B, Walker N F, et al. The immune mechanisms of lung parenchymal damage in tuberculosis and the role of host-directed therapy. Front Microbiol 2018; 9: 2603.
13 Tiberi S, du Plessis N, Wald G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis 2018; 18: e183–e198.
14 Merkus P J, ten Have-Opbroek A A, Quanjer P H. Human lung growth: a review. Pediatr Pulmonol 1996; 21: 383–397.
15 Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory health and disease. Lancet Respir Med 2013; 1: 728–742.
16 Graham S M, Cuevas L E, Jean-Philippe P, et al. Clinical case definitions for classification of intrathoracic tuberculosis in children: an update. Clin Infect Dis 2015; 61(Suppl 3): S179–S187.
17 Chakaya J, Kirenga B, Getahun H. Long term complications after completion of pulmonary tuberculosis treatment: a quest for a public health approach. J Clin Tuberc Other Mycobact Dis 2016; 3: 10–12.
18 Hsu D, Irfan M, Jabeen K, et al. Post tuberculosis treatment infectious complications. Int J Infect Dis 2020; 92: S41–S45.
19 Muñoz-Torrico M, Rendon A, Centis R, et al. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis? J Bras Pneumol 2016; 42: 374–385.
20 Migliori G B, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis 2020; 92: S15–S25.
21 Akkerman O W, ter Beck L, Centis R, et al. Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. Int J Infect Dis 2020; 92: S10–S14.
22 Visca D, Zampogna E, Sotgiu G, et al. Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. Eur Respir J 2019; 53: 1802184.
23 Tiberi S, Muñoz-Torrico M, Rahman A, et al. Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. J Bras Pneumol 2019; 45: e20180324.
24 Uplekar M, Weil D, Lonroth K, et al. WHO’s new end TB strategy. Lancet 2015; 385: 1799–1801.
25 André E, Rusumba O, Evans C A, et al. Patient-led active tuberculosis case-finding in the Democratic Republic of the Congo. Bull World Health Organ 2018; 96: 522–530.
26 Berrocal-Almanza L C, Botticello J, Piotrowski H, et al. Engaging with civil society to improve access to LTBI screening for new migrants in England: a qualitative study. Int J Tuberc Lung Dis 2019; 23: 563–570.
27 Wingfield T, Tovar M A, Datta S, et al. Addressing social determinants to end tuberculosis. Lancet 2018; 391: 1129–1132.
28 Courtwright A, Turner A N. Tuberculosis and stigmatization: pathways and interventions. Public Health Rep 2010; 125 (Suppl): 34–42.
29 Sommerland N, Wouters E, Mitchell E M H, et al. Evidence-based interventions to reduce tuberculosis stigma: a systematic review. Int J Tuberc Lung Dis 2017; 21: 81–86.
30 Deluca A, Lessem E, Wegener D, et al. The evolving role of advocacy in tuberculosis. Lancet Respir Med 2014; 2: 258–259.
31 Marx F M, Yaqoubi R, Menzies N A, et al. Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. Lancet Glob Health 2019; 6: e426–e435.
La TB es una enfermedad curable, pero con frecuencia las personas conservan discapacidades crónicas físicas y psicosociales; hasta la fecha, no obstante, se ha prestado poca atención a estas consecuencias. El Primer Simposio Internacional Post tuberculosis se dedicó exclusivamente a las discapacidades posteriores a la TB y abordó una diversidad de temas multidisciplinarios. Mediante el método Delphi se logró la unanimidad alrededor de los términos «post tuberculosis», «enfermedad pulmonar post tuberculosis» (PTLD) y «bienestar económico, social y psicosocial post tuberculosis», con el fin de superar la dificultad histórica de una terminología variable en las publicaciones científicas. Se propuso por consenso una definición de caso mínima para la PTLD en los adultos y los niños. La falta de evidencia suficiente obstaculizó la formulación de recomendaciones definitivas en la mayoría de las esferas, incluida la prevención y el tratamiento de la PTLD, pero se puso de manifiesto la urgente necesidad de nuevas investigaciones y se definieron las prioridades. La heterogeneidad de los resultados respiratorios y los métodos de investigación utilizados anteriormente complicó la estimación exacta de la carga de la enfermedad. Sin embargo, se pudo proponer de manera unánime un conjunto de herramientas para la medición de la PTLD en el futuro y los tipos de PTLD que se tendrían en cuenta. Se estableció la importancia de las consecuencias extrapulmonares y la discapacidad progresiva a lo largo de la vida, incluida la recaída de la TB y el aumento de la mortalidad. Los portavoces de los pacientes destacaron la necesidad de abordar las repercusiones psicológicas y sociales post tuberculosis y solicitaron la elaboración de directrices clínicas. Se precisa con urgencia una mayor sensibilización a las complicaciones posteriores a la TB y nuevas investigaciones que estudien este problema.